MRFR offers a Phenomenal Analysis of Antibody Drug Conjugate Market by Segmentation, Regional Analysis, Top Companies, Scope, and Applications.
— Market Highlights:
Global Antibody Drug Conjugate Market is set to proliferate saliently at a CAGR of 19% during the forecast period 2017 to 2023. These drug conjugates are regarded as the new age of therapeutic agents. The efficiency of the drug in treating diseases has propelled demand in the global market, and the trend is likely to perpetuate over the next few years.
Increased investments in research & developments in the antibody drug conjugate market are further expected to augment the market size. Nevertheless, the high cost associated with the procedures is likely to hold the market growth through the projection period.
Request Sample Copy at https://www.marketresearchfuture.com/sample_request/1113
The effects of targeting specific cells coupled with the killing ability of cytotoxic drugs make this antibody drug conjugate the ideal choice for the treatment of various cancers. The rising prevalence of cancer all across the globe has catapulted the antibody drug conjugate market on an upward trajectory. Additionally, the advancements in medical technologies are anticipated to drive the growth of the global market by enhancing the accuracy of the drug.
Some of the key players profiled by MRFR are Seattle Genetics (U.S.), ImmunoGen, Inc. (U.S.), Roche Holding AG (Switzerland), Antikor (U.K.), Immunomedics (U.S.), Pfizer Inc. (U.S.), Celldex Therapeutics (U.S.), Millennium Pharmaceuticals (U.S.), AbbVie Inc. (U.S.), Genentech (U.S.), Concortis Biotherapeutics (U.S.), Agensys, Inc. (U.S.), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (U.S.), Heidelberg Pharma (Germany), Oxford BioTherapeutics (U.S.), Mersana Therapeutics (U.S.), and Synthon (U.S.).
By type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.
By application, the antibody drug conjugate market has been segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further sub-segmented into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).
By product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.
By technology, the antibody drug conjugate market has been segmented into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.
By end-user, the global antibody drug conjugate market is segmented into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.
By region, the global antibody drug conjugate market is segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas dominate the global market owing to technological innovations, manufacturing process advancements, the contribution of nanotechnology, etc. Led by the U.S., the region is anticipated to retain its pole position through the assessment period. Europe is likely to retain its second spot trailed by the Asia Pacific which is an emerging market for antibody drug conjugate.
Browse Complete 140 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures at https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Name: Sumaiya Khan
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Release ID: 485139